There are 3484 resources available
Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours - No
Presenter: Yannis Metaxas
Session: YO Boxing session
Resources:
Slides
Webcast
Q&A and Discussion
Presenter: All Speakers
Session: Interdisciplinary management of advanced and functional digestive neuroendocrine tumours
Resources:
Slides
Webcast
Discussion led by Chairs
Presenter: All Speakers
Session: YO Boxing session
Resources:
Slides
Webcast
Invited Discussant LBA41 and LBA42
Presenter: Domenica Lorusso
Session: Proffered Paper session 2 - Gynaecological cancers
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 2 - Gynaecological cancers
Resources:
Webcast
2359O - Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
Presenter: Arlene Siefker-Radtke
Session: Proffered Paper session 1 - Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA68 - FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC
Presenter: David Planchard
Session: Mini oral session 1 - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Risk assessment stratification
Presenter: Nadia Harbeck
Session: Unravelling choices for adjuvant endocrine therapy in HR+ early breast cancer
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Paul Baas
Session: Open questions in the management of mesothelioma
Resources:
Slides
Webcast
Screening programmes 20 years later: Lessons learned and how to move on?
Presenter: Monique van Leerdam
Session: Fight the enemy as soon as possible: News and views in the management of early stages colorectal cancer (CRC)
Resources:
Slides
Webcast